BAX
Baxter International
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About BAX
Baxter International Inc.
A commercial-stage company focused on transforming the lives of people with fluid overload
Healthcare Equipment and Supplies
Invalid Date
05/15/1961
New York Stock Exchange
38000
12-31
Common stock
One Baxter Parkway, Deerfield, Illinois, 60015
Development, production and sales of medical equipment and products
Baxter International Inc. was incorporated in 1931 under the laws of the State of Delaware. The company offers a broad range of basic healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapy; inhaled anesthesia; generic injections; surgical hemostatic and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technology; and respiratory health equipment.
Company Financials
EPS
BAX has released its 2024 Q4 earnings. EPS was reported at 0.58, versus the expected 0.52, beating expectations. The chart below visualizes how BAX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BAX has released its 2024 Q4 earnings report, with revenue of 2.75B, reflecting a YoY change of 0.99%, and net profit of -510.00M, showing a YoY change of -307.32%. The Sankey diagram below clearly presents BAX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
